Vanguard Global Advisers
ADMA icon

Vanguard Global Advisers’s ADMA Biologics ADMA Stock Holding History

Vanguard Global Advisers’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$768K Sell
91,748
-4,582
-5% -$41.8K ﹤0.01% 1894
2026
Q1 		$868K Buy
+96,330
New +$1.52M ﹤0.01% 1733

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Global Advisers's ADMA Position: Q2 2026 in Review

Vanguard Global Advisers reduced its ADMA Biologics (ADMA) stake by 4.8% in Q2 2026, selling an estimated $41.8K and leaving 91,748 shares worth $768K. The position accounts for ﹤0.01% of the portfolio, ranked #1894.

Vanguard Global Advisers first reported a position in ADMA in Q1 2026 and has held it in 2 quarters since. The position peaked at $868K in Q1 2026. 319 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Vanguard Global Advisers held 91,748 shares of ADMA Biologics worth $768K as of Q2 2026.
  • Vanguard Global Advisers sold 4,582 ADMA Biologics shares in Q2 2026, an estimated $41.8K.
  • ADMA Biologics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1894 holding.
  • Vanguard Global Advisers first reported a position in ADMA Biologics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's ADMA Biologics position peaked at $868K in Q1 2026.
  • 319 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.